... Food and Drug Administration Novartis Receives Third FDA Approval for Oral Fabhalta (Iptacopan) — The First and Only Treatment Approved in C3 Glomerulopathy (C3G) — Novartis Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy — Kidney International Reports Novartis Oral Fabhalta (Iptacopan) Sustained Clinically Meaningful Results at ...
7 C3 Glomerulopathy Treatment Options That Can Help
... Food and Drug Administration Novartis Receives Third FDA Approval for Oral Fabhalta (Iptacopan) — The First and Only Treatment Approved in C3 Glomerulopathy (C3G) — Novartis Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy — Kidney International Reports Novartis Oral Fabhalta (Iptacopan) Sustained Clinically Meaningful Results at ...
... That began to change in March 2025, when the FDA approved iptacopan (Fabhalta) for adults with C3G and IgA nephropathy (IgAN). Iptacopan also works by blocking part of the complement system and helps lower protein levels in the urine. ...
... Food and Drug Administration Novartis Receives Third FDA Approval for Oral Fabhalta (Iptacopan) — The First and Only Treatment Approved in C3 Glomerulopathy (C3G) — Novartis ...
Dense Deposit Disease: 5 Facts To Know
... Food and Drug Administration Novartis Receives Third FDA Approval for Oral Fabhalta (Iptacopan) — The First and Only Treatment Approved in C3 Glomerulopathy (C3G) — Novartis ...
... Food and Drug Administration FDA Grants Fabhalta Accelerated Approval for Treatment of IgA Nephropathy in Adults — NephCure Sparsentan: First Approval — Drugs FDA Approves First Treatment for Adults With Complement 3 Glomerulopathy, a Rare Kidney Disease, To Reduce Proteinuria — U.S. ...
Clinical Trials for Rare Kidney Disease: 6 Facts To Know
... Food and Drug Administration FDA Grants Fabhalta Accelerated Approval for Treatment of IgA Nephropathy in Adults — NephCure Sparsentan: First Approval — Drugs FDA Approves First Treatment for Adults With Complement 3 Glomerulopathy, a Rare Kidney Disease, To Reduce Proteinuria — U.S. ...
... Food and Drug Administration Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients With C3 Glomerulopathy (C3G) — Novartis Novartis Presents Latest Phase III Fabhalta (Iptacopan) Data in C3 Glomerulopathy (C3G) Showing Clinically Meaningful and Statistically ...
C3 Glomerulopathy Life Expectancy: Dialysis and Other Factors
... Food and Drug Administration Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients With C3 Glomerulopathy (C3G) — Novartis Novartis Presents Latest Phase III Fabhalta (Iptacopan) Data in C3 Glomerulopathy (C3G) Showing Clinically Meaningful and Statistically ...
... Recently, the FDA approved two treatments to help lower protein in the urine: A complement factor B inhibitor called iptacopan (Fabhalta) for adults with C3G A C3 inhibitor called pegcetacoplan (Empaveli) for people 12 and older with C3G and primary IC-MPGN Other complement blockers for these diseases are still being studied.Controlling InfectionsSometimes ...
Treating Rare Kidney Disease: Why the Underlying Cause Matters for C3G and IC-MPGN
... Recently, the FDA approved two treatments to help lower protein in the urine: A complement factor B inhibitor called iptacopan (Fabhalta) for adults with C3G A C3 inhibitor called pegcetacoplan (Empaveli) for people 12 and older with C3G and primary IC-MPGN Other complement blockers for these diseases are still being studied.Controlling InfectionsSometimes ...
... Food and Drug Administration (FDA) approved the first drug specifically for C3G — iptacopan (Fabhalta). In July 2025, the FDA approved pegcetacoplan (Empaveli) to reduce proteinuria in people with C3G. Pegcetacoplan is also approved for immune-complex membranoproliferative glomerulonephritis (IC-MPGN). ...
What Is C3 Glomerulopathy? 7 Facts
... Food and Drug Administration (FDA) approved the first drug specifically for C3G — iptacopan (Fabhalta). In July 2025, the FDA approved pegcetacoplan (Empaveli) to reduce proteinuria in people with C3G. Pegcetacoplan is also approved for immune-complex membranoproliferative glomerulonephritis (IC-MPGN). ...
Join
Your Privacy Choices
